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www.carjonline.orgComputed tomography (CT) angiography (CTA) and
magnetic resonance (MR) angiography (MRA) are 2
modalities that have revolutionized the field of diagnostic
vascular imaging. Conventional catheter angiography, which
was once the gold standard, is now being replaced by CTA
and MRA because of their lower cost and noninvasiveness.
Advancements in cross-sectional imaging include higher
spatial and temporal resolution, as well as the ability to
construct three-dimensional (3D) images from volumetric
data and to view vessels from multiple angles [1].
CTA is traditionally more widely used than MRA, mainly
because of availability and greater CT expertise. Other
advantages of CTA over MRA include faster acquisition times,
higher spatial resolution, and utility in patients with contra-
indications to MR imaging, including certain aneurysm clips,
cochlear implants, pacemakers, and claustrophobia [1,2].
Current uses of CTA are many, including perioperative
imaging and planning of endovascular aneurysm repairs
(EVAR) and imaging of the abdominal aorta and visceral
vessels [3]. Disadvantages of CTA include the use of ionizing
radiation and iodinated nephrotoxic contrast material, 2
factors that make MRA a more desirable modality.
Using MR to delineate vascular anatomy has changed
dramatically since first described in 1985 by Wedeen et al
[4]. Technology continuously evolves and provides more
advanced equipment and complex software, which is faster
and provides more detailed information. MR sequences such
as phase-contrast (PC) MRA (PC-MRA) and time-of-flight
(TOF) MRA (TOF-MRA) provide reasonable depictions of
the vascular anatomy without contrast. Research into non-
nephrotoxic, gadolinium-based contrast agents has paved the
way for contrast-enhanced MRA (CE-MRA), which today is
widely used in clinical practice [5].
MRA is gaining popularity as applications increase image
quality and decrease acquisition time. Dynamic MRA
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doi:10.1016/j.carj.2009.05.008acquisitions (time-resolved imaging of contrast kinetics
[TRICKS; GE, Buckinghamshire, United Kingdom] and
syngo TWIST [Siemens, Munich, Germany]) are relatively
new and beneficial techniques that shorten acquisition times
by obviating contrast-injection timing tests [6,7], acquire
temporal data that can be reviewed as a cine loop, and
replicate conventional digital subtraction angiography (DSA)
sequences. Desired images can then be selected retrospec-
tively to create 3D images.
Advantages of MRA over CTA include increased signal-
to-noise ratio, easier 3D postprocessing, and utility in
patients with renal dysfunction, such as diabetics [2,3]. In
patients who require recurrent follow-up imaging, MRA is
superior, given its lack of ionizing radiation. MRA is often
used to image the visceral aortic branches and in many
centers is the gold standard for visualizing the renal arteries.
MRA has also been shown to be valuable in the preproce-
dural and follow-up of patients undergoing aortic EVAR. In
the planning stages, CE-MRA has been shown not only to be
as accurate as CTA but able to provide functional, hemo-
dynamic information that CTA cannot. As well, common
delayed complications, for example, endoleak, are more
conspicuous with contrast-enhanced MRA [8]. Other appli-
cations of MRA include cerebrovascular imaging and visu-
alization of the infrainguinal arterial system [2].
In this article, the investigators provide a pictorial journey
through some of the many applications of body MRA.
Hyperlinks to web videos are provided to see some of these
applications in real time. Also, future applications of MRA
and the impact of functional information derived from MR
will be discussed.
Vascular Thoracic Outlet Syndrome
The thoracic outlet comprises 3 spaces: the interscalene
triangle, the costoclavicular space, and the retropectoralis
minor space (subcoracoid tunnel) [9]. Vascular or nervous
compression within one of these spaces leads to thoracic
outlet syndrome (TOS). Clinical diagnosis is made through
eliciting symptoms through various dynamic movements ofAll rights reserved.
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similar symptoms during abduction maneuvers, imaging
studies should confirm the diagnosis [11]. Several studies
showed the usefulness of MR in delineating neurovascular
structures as they pass through the aforementioned spaces
Figure 1. Time-resolved imaging of contrast kinetics (TRICKS) magnetic
resonance (MR) angiography (MRA) of the thoracic outlet in a 55-year-old
man in the challenged positioning (arm abducted), showing critical
mechanical stenosis of the left subclavian vein (red arrow). There are
multiple collaterals, showing holdup of contrast proximally and peripherally.
Technique: 7.5 mL Gadovist (Berlex; Bayer Healthcare Pharmaceuticals,
Montville, NJ), 20 mL NS push, matrix 256  192, 2-mm thick, TR: 1 sec.
NS ¼ normal saline.[11,12]. MR imaging of suspected vascular TOS is con-
ducted with the arm in 2 positions: adduction, followed by
hyperabduction. If imaging demonstrates compression of
either the subclavian artery or vein and is correlated with
clinical symptoms, then a diagnosis of vascular TOS can be
made [11]. See Figures 1 and 2 for examples of this.
Conventional angiography has traditionally been the gold
standard for imaging vascular TOS because of its high
resolution, however, it is invasive, requires the use of
iodinated contrast, and does not always allow the cause of
the compression to be determined [13]. MRA is perfectly
suited to the imaging of vascular TOS, with its high spatial
resolution, noninvasiveness, and short acquisition times [14].
Use of MRA to evaluate TOS requires 2 positions, neutral
and challenged, and 2 separate contrast injections, but can be
dynamically interrogated by using TRICKS or TWIST
techniques. TRICKS in real time is demonstrated in Video 1.
Dynamic MRA avoids the potential for residual intravascular
contrast contaminations and reduced signal-to-noise ratios.
Two separate static MRA studies examined this potential
pitfall and concluded that image quality was rarely impaired
by the increased background contrast, because they were
able to achieve detailed images of both the arteries and veins
in both arm positions [11,15]. MRA, with its superior soft-
tissue imaging capabilities, has the distinct advantage of
demonstrating the underlying cause of TOS, whether it is
congenital bony or fibromuscular anomalies, trauma, or
posture. Ultimately, TOS is a surgical and/or clinical diag-
nosis, and a multidisciplinary approach is paramount.
Peripheral Arterial Disease
Peripheral MRA is a safe and noninvasive procedure that
can be used to evaluate renal, aortoiliac, and distal runoffFigure 2. Bilateral subclavian vein stenosis. (A) Conventional angiogram, showing residual thrombosis in the right subclavian vein. Note the meniscus, which
represents an intraluminal thrombus. (B) Second conventional angiogram in the same patient, demonstrating moderate stenosis of the left subclavian vein
(green arrow). (C) TRICKS MRA of both arms in the challenged positioning (both arms abducted), showing congruency with the digital subtraction
angiography (DSA) venogram: right subclavian vein residual thrombosis and moderate stenosis of the left subclavian vein (red arrow). Technique: 7.5 mL
Gadovist, 15 mL NS bolus push, matrix 256  192, 2-mm thick, TR: 2 sec.
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to the foot as the contrast agent flows through the vessels.
MRA is highly specific and sensitive in detecting stenoses
and aneurysms in the aortoiliac and distal femoral vessels.
Peripheral arterial disease (PAD) is defined as the mani-
festation of atherosclerosis in the lower limb distal to the aortic
bifurcation. Initial presentation of PAD is usually intermittent
claudication, which can progress to critical limb ischemia.
Imaging of PAD is indicated when the symptoms become
apparent and intervention by revascularization is considered.
The first randomized controlled trial that compared CTA and
MRA in evaluating PAD was performed recently, and there
was no significant difference in clinical utility and patient
outcomes between the 2 modalities [16], although CTA did
have the advantages of lower total diagnostic costs and greater
therapeutic confidence. However, with the annual rapid
increase in renal impaired patients, MRA safety and its
applications are becoming far more robust. As MRA experi-
ence increases diagnostic confidence will follow.
It has been suggested that diagnostic utility of MRA and
CTA in detecting PAD is variable, depending on the
anatomic level of the disease and the degree of venous
contamination [17,18]. The infrapopliteal region is poorly
visualized by CTA because of the small-diameter arteries
[19], and highly calcified vessels are the nemesis of CTA
luminal evaluation. MRA contrast media fills the vessel
lumen, and the inherent MR and subtraction techniques
circumvent calcification artifacts, altogether making its
utility in patients with diabetes and with calcified vessels
superior to CTA and DSA. Also, dynamic MRA techniques
can replicate real-time inflow of contrast media, as in DSA,
and show superior vessel analysis of stenoses, compared with
standard, nondirectional, MRA and CTA techniques. Exam-
ples of the dynamic nature of MRA and its utility in evalu-
ating PAD are seen in Figure 3 and Videos 2 and 3. Also, the
sequelae of atherosclerosis is demonstrated in Video 4, but
the case involves the vessels of the wrist and hand.
Renal Artery Stenosis
In 1934, Goldblatt et al outlined the pathophysiology of
renal artery stenosis (RAS) and its association with systemic
hypertension [20]. Subsequent research demonstrated the
complexity of this relationship, because RAS may occur
alone or in association with systemic hypertension and/or
renal insufficiency. Individuals with essential or primary
hypertension can also have RAS, which, even if corrected,
the individuals’ blood pressure remains elevated [21].
The majority of cases of RAS are caused by either
atherosclerosis or fibromuscular dysplasia. Atherosclerosis
accounts for up to 90% of cases of RAS, and its prevalence
increases with age and other comorbidities, such as diabetes
and coronary artery disease [5,21]. It usually involves the
ostium and proximal third of the main renal artery and per-
irenal aorta [22,23]. Fibromuscular dysplasia covers a group
of conditions that involve fibrous or muscular proliferation
with involvement of the vascular media (90% of the time). Itrarely progresses to complete occlusion of the artery when
compared with atherosclerotic RAS.
RAS severe enough to decrease renal perfusion initiates
the renin-angiotensin system and elevates systemic blood
pressure. The ultimate goal is to noninvasively evaluate
patients who are hypertensive and with as little effect on the
kidneys as possible. Although DSA is the gold standard for
anatomic delineation, complicating factors, such as contrast
nephrotoxicity and possible anaphylaxis, makes it less
attractive. A meta-analysis that compared noninvasive or
minimally invasive diagnostic techniques currently used
found that CTA and MRA were superior to ultrasound,
captopril renal scintigraphy, and the captopril test [24].
CE-MRA has become the imaging modality of choice,
because not only is it noninvasive but it uses non-nephrotoxic
contrast agents to delineate renovascular pathology [25e28].
Studies since 1994 have shown high sensitivity and speci-
ficity for both nonenhanced and contrast-enhanced MRA in
the detection of RAS [22,29]. MRA has also shown its value
in delineating the vascular anatomy before revascularization,
assessing renal bypass grafts, and evaluating vascular
Figure 3. Clinical history of right leg claudication. This case demonstrates
the directional differences between conventional contrast-enhanced (CE)
MRA and temporal MRA studies (TRICKS). (A) CE-MRA, in which
injected contrast fills as many vessels as possible over time, and the resultant
display erroneously represents a falsely patent artery by retrograde arterial
flow (blue arrow). (B) Temporal MRA (TRICKS) accurately identifying an
occlusion of the same peroneal artery because of multiple progressive MRA
images and prograde filling (red arrow) of the anterior tibial and posterior
tibial arteries with retrograde filling of the peroneal artery. There is no
sacrifice of image quality or signal-to-noise ratio because of temporal speed.
Technique: 7.5 mL Gadovist, 20 mL NS bolus push, matrix 256  160,
2-mm thick, Sp 1 mm, TR: 2 sec. Sp ¼ spacing.
Figure 4. (AeC) Renal artery stenosis. CE-MRA examination of the right renal artery, showing mildly irregular but patent renal arterial lumen after 6-mm
balloon angioplasty. In these situations, noninvasive MRA surveillance is recommended every 6 months for the first year, with another examination if the
patient’s blood pressure, creatinine, and/or glomerular filtration rate levels become abnormal.
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MRA also provides functional information concerning renal
hemodynamics, such as renal perfusion, glomerular filtration
rates (GFR), tubular concentration and transit, diffusion, and
oxygenation [27,30,31]. The application of MRA in the
evaluation of RAS is shown in Figures 4e6.
When evaluating stenotic lesions, widely accepted crite-
rion is that a stenosis comprising an perpendicular area of
75% (theoretically corresponding to 50% diameter) is
considered hemodynamically significant [32]. Schoenberg
et al [26] demonstrated that evaluating the perpendicular area
was far more reliable than measuring the stenosis diameter.
However, some investigators would argue that revasculari-
zation of a severely stenotic lesion may be unnecessary if
renal parenchymal impairment has already occurred. Renal
compromise would mean slow blood flow and the absence of
a pressure gradient beyond the stenotic lesion [31].
Before CE-MRA, noncontrast techniques, such as TOF
and PC, were used to delineate vascular anatomy, however,
they were limited by diminished vascular flow in patients
with severe stenosis or parenchymal disease and respiratory
motion artifact. Many centers today combine CE-MRA
with noncontrast two-dimensional (2D) and 3D cine PC
sequences to add functional information to the anatomic
information. Combining multiple sequences within a single
examination provides a plethora of diagnostic information:
anatomy of the kidney and adrenals (morphology, presence
of cysts or neoplasms), arterial and venous anatomy, gado-
linium transit and clearance rate, pressure gradients, and
measurement of blood flow to each kidney [27].
Some patients receive renal artery endoluminal MR-
compatible stents to correct the RAS and warrant the safestmeans of follow-up. These new MR-compatible stents are
composed of cobalt chromium and allow evaluation of renal
artery patency after intervention. Technically, the shortest TE
should be used to decrease dephasing, with a bandwidth
around 62.5 KHz. A high flip-angle (commonly 60) is
needed to avoid radiofrequency (RF) shielding. Examples of
RAS with MR-compatible stents are shown in Figures 4e6.
Role of MRA in Aortic Disease and Endovascular
Aneurysmal Repair
MRA is capable of evaluating the aorta in a noninvasive
3D manner with innumerable postprocessing angles and
views. Aortic diseases seen with MRA can be evaluated with
respect to the lumen and to mural and extramural structures.
Aortic lumens can retain plaque, tumour, or thrombus,
whereas regional or adjacent structures may relate to the
underlying vascular disease, all within diagnostic capabilities
of MR and MRA. The aortic wall can also be evaluated in
disease processes, such as inflammatory aortitis from idio-
pathic, infectious, or autoimmune etiologies. Examples of
inflammatory abdominal aortic aneurysm (AAA) are seen in
Figure 7 and Video 5. MRA with fat saturation, as well as
pre- and postgadolinium sequences can clearly identify the
inflamed and enhancing aortic wall and fibrous thickening, as
well as aortic dilatation and/or stenoses.
Repair of AAAs has changed dramatically over the past
decade. Since the early clinical trials described by Parodi
et al [33], EVAR has evolved as a widely used, less-invasive
alternative for treating patients with AAAs [34]. EVAR is
associated with reduced blood loss, fewer postoperative
complications, decreased need for intensive care unit stays,
Figure 5. A 58-year-old woman with a clinical history of hypertension and elevated creatinine. (A) Prestent MRA, demonstrating severe left renal artery
stenosis (green arrow) with high flow signal void in renal ostium. (B) Prestent axial multiplanar reconstructed (MPR) allows for the delineation of the stenosis
length and underlying native renal calibre. This facilitates preprocedural selection of the most accurate and safe renal artery stent. Technique: MRA 7.5 mL
Gadovist, 15 mL NS bolus push, matrix 256  192, 0.71 NEX, 2.4-mm thick, Sp 1.2 mm. (C, D) Two DSA images show severe left renal artery stenosis with
normal nephrogram. (E) DSA image, showing a 7  12-mm MR-compatible stent after balloon angioplasty and reveals excellent improvement in vessel
calibre. (F, G) Post-MRA visualization of left renal artery with MR compatible cobalt chromium Racer (Medtronic, Minneapolis, MN) stent in situ. Sagittal (F)
and MPR (G) images further delineate the calibre of the stent. NEX ¼ number of excitations.
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open repair [35]. These advances, however, have precipitated
ever-increasing demands on diagnostic imaging to providehigh-resolution, accurate analyses of the abdominal vascu-
lature. In the EVAR planning stages, accurate morphologic
measurements of the aorta and adjacent vasculature must be
Figure 6. A 73-year-old woman with bilateral renal artery stenoses, who had previously had a left stainless steel renal stent inserted. (A, B) DSA-guided
insertion of MR-compatible cobalt chromium Racer stent in the right renal artery. The stainless steel stent in the left renal artery is indicated by the red arrow.
(CeF) PosteMR-compatible Racer stent insertion. Multiple direct coronal and reconstructed axial MRA projections of the renal arteries, as well as MPR and
vessel analysis reformations of the right renal artery after stenting. Note the significant metallic susceptibility artifact in the region of the left renal artery with
its stainless steel stent (E). The orange arrow (F) points to the stainless steel stent in the left renal artery, which makes interpretation of the arterial lumen
nondiagnostic.
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to complications, such as endoleak and stent migration [37].
Morphologic measurements include length and diameter of
the proximal aortic neck, aortic contour, delineation of
thrombus and/or calcification, angle between aortic neck and
suprarenal aorta, calculated stent-graft length, and charac-
terization of the iliac and renal arteries [38]. An example of
an MRA image obtained for preoperative EVAR workup is
given in Figure 8, and the utility of MRA in evaluating
EVAR after surgery is shown in Video 6.
Various imaging modalities have been assayed, however,
CTA and MRA have emerged as the most reliable modalities for
pre- and postprocedural assessment [39,40]. MRA of patients
with EVAR requires the implantation of MR-compatible nitinol
products. MRA has not only been shown to be a reliable alter-
native [41] but can supercede the capabilities of CTA when
evaluating for the presence of endoleak [42,43]. Some investi-
gators found that serious complications, for example, endo-
leaks, are better delineated by MRA [40,43]. See Figure 9 for an
example of the capability of MRA in detecting endoleak.MRA images are obtained as a true 3D data set, which
supercedes the 2D images of DSA and Doppler ultrasound
[26]. With advancement of technology and faster scanning
times, achieving optimal blood-to-background contrast has
become more difficult. Gadobutrol (gadolinium-DO3A-butriol,
Gadovist; Bayer Schering Pharma, Leverkusen, Germany), one
of the newer MRA contrast agents, can be used at 1.0 mmol/mL
(most solutions for CE-MRA are 0.5 mmol/mL), without
adversely affecting electrocardiographic measurements and
renal function [25]. The higher concentration thus provides
higher intravascular signal and enhances blood-to-background
contrast. Other advantages of MRA reports by some investi-
gators have been significantly decreased postprocessing times
with MRA, up to 60 times shorter than CTA [38,39,44].
A consistent shortcoming of MRA has been its higher cost
and decreased availability when compared with CTA. As
well, scanning time is longer, which can be difficult for some
patients, and, therefore, for emergent cases, CTA is more
appropriate [5]. Delineating small accessory renal vessels
and grading RAS has been shown to be more sensitive and
Figure 7. Inflammatory abdominal aortic aneurysm (AAA) treated with a Medtronic nitinol stent 1 month earlier. (A) Preoperative Gadovist-enhanced MRA of
the abdominal aorta clearly showing enhancing mural thickening of the infrarenal aorta (red arrows). Intraluminal aortic thrombus (black) and luminal contrast
(grey) are also well delineated. (B) MRA MIP, showing visceral anatomy and luminal aortic contours. (C) Postoperative coronal MRA of MR-compatible
(nitinol-Medtronic) EVAR, with patent limb grafts and persistent aortic mural thickening and enhancement. No evidence of endoleak. MIP ¼ maximum
intensity projection.
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calcifications has also been shown to be more accurate with
CTA, which is important for planning of EVAR cases.
Overall, MRA has consistently demonstrated its ability to
provide accurate information necessary for EVAR, parallel
with that provided by CTA and/or DSA [38,45].
Functional information gleaned from MRA may ultimately
tip the scale when deciding between MRA and CTA. Anatom-
ical information demonstrated on MRA is superior to conven-
tional DSA and continually competes with CTA as a viable
alternative. However, anatomic information may not always
coincide with physiologic consequences, as is the case with
RAS. Hemodynamic information, such as flow velocity and
organ perfusion, elucidates the lesions that are actually
contributing to vascular compromise and organ demise. In
addition, this added information can be acquired while anatomic
outlines are being made, which means that the patient does not
have to return for another examination. For this reason, MRA
has proven to be a valuable tool, able to manage a patient from
the preprocedural evaluation and morphologic assessment all
the way through the postprocedural surveillance stages.
Dynamic MRA Bolus Chase Third Station Evaluation:
TRICKS and TWIST
These are relatively new and beneficial techniques that
shorten acquisition times by obviating contrast injection
timing tests [6,7], acquire temporal data that can be reviewed
as a cine loop, and replicate conventional DSA sequences.
TRICKS and TWIST are innovative techniques that capi-
talize on the existing technology of standard bolus chase CE-
MRA. Before CE-MRA, 2D TOF-MRA emerged as anattractive alternative to DSA, however, drawbacks, such as
lengthy examination times, movement artifact, and significant
signal-to-noise losses, hindered its widespread acceptance [5].
With the inception of CE-MRA, 3D images are acquired faster
and with enhanced vessel-to-background contrast, without
being as susceptible to artifacts that complicate TOF-MRA.
To properly image the vasculature as contrast passes
through, careful planning must be done to time the procedure
for maximum vessel signal. Images that are 2D are used with
a test bolus to measure the delay between injection and
maximum vessel filling, at which time data sampling should
take place. Software packages such as BolusTrak (Philips,
Best, The Netherlands) and CareBolus (Siemens) provided
a streamlined method of automating this process that removed
the need for a test bolus scan. ‘‘Real-time’’ bolus monitoring
allowed the entire contrast volume to be administered while
the true 3D CE-MRA examination was taking place.
One of the major issues complicating CE-MRA images has
been background venous enhancement. A recent technique
described by Korosec et al [6] involves repetitively sampling the
center of k-space while leaving peripheral data to be collected
towards the end of the examination. Both data sets are then
temporally interpolated to provide images with enhanced
spatial resolution, increased vessel-to-background contrast, and
reduced contaminating venous enhancement. Also, TRICKS
obviates the need for timing software and other strategies to
reduce venous enhancement, such as image masking [5].
Potential Complications and Controversies of MRA
Contrast Agents
Despite millions of patients receiving MRA contrast
media, many of whom are specifically selected because of
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a progressive, irreversible, and potentially fatal disease called
nephrogenic systemic fibrosis (NSF). Just over 100 world-
wide, non-Canadian, cases of NSF have been reported after
the administration of gadolinium. Some patients with NSF
were never exposed to gadolinium, whereas others were
thought to be a higher risk because of their lower GFRs.
Patients with NSF can develop thickening of the skin and
connective tissues that causes significant morbidity that to
date is untreatable. There are ongoing efforts to validate and
isolate the actual causes of NSF and their potential causal
Figure 8. MRA for preoperative endovascular aneurysm repair (EVAR)
workup. Accurate spatial resolution allows endovascular radiologists to
document renal anatomy, infrarenal aortic neck lengths, and pelvic arterial
dimensions.relationship with gadolinium-based contrast agents (GBCA).
A few studies found that the majority of cases originated
from Omniscan (gadodiamide; GE Healthcare, Olso,
Norway) [46e48]. On May 23, 2007, the Food and Drug
Administration (FDA) called attention to observed serious
adverse reactions of patients with NSF and with renal failure,
just before or after liver transplantation, or those with chronic
liver disease.
There are theories that NSF is related to GBCA chelation
architecture, severity of renal failure, and dose dependence
[46e50]. The possibility of transmetallation and liberation
of free gadolinium from a chelating agent may be 1000 times
higher in an agent like gadodiamide. Macrocyclic GBCAs
may be more resistant to cleavage and/or release of free
toxic gadolinium [48e50]. Recommendations to reduce the
risk of NSF include obtaining both creatinine and GFR
values, specifically in patients with severe renal insuffi-
ciency, stage 4 or higher, or with a GFR <30 mL/min per
1.73 m2; weigh the risk of CE-MR imaging in patients with
impaired renal function vs the risk without GBCA, not test at
all, or use CE CT with ionizing radiation. In all cases in
which significant chronic renal failure (CRF) cases are
unavoidable, the GBCAs should be minimized [48e50]. The
FDA suggests that NSF can occur after use of any of the
GBCAs in certain patients and that ‘‘black box’’ warnings be
added to product labeling of all GBCAs, further suggesting
that ‘‘GBCAs play a role in NSF development’’ but have not
been ‘‘definitively determined’’ to do so (FDA web site). For
more information see www.fda.gov/cder/drug/infopage/gcca/
default.htm.
New and Future Experimental MRA Contrast Agents
Intravascular and plaque-specific contrast agents are 2
examples of new and future compounds being used in MR
vascular imaging. MRA contrast media currently is based on
extracellular mechanics that rapidly extravasates, limiting
study acquisition times, spatial resolution, and contrast-
to-noise ratios. The creation of intravascular agents that are
Figure 9. Axial MRA image of postoperative EVAR of infrarenal AAA.
Contrast is seen in each widely patent limb graft. However, there is contrast
seen in the aneurysm sac external to the graft stent (green arrows) consistent
with a significant type II endoleak.
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and allow for the reduction of voxel sets from 1e2.5 mm3
down to less than 0.5 mm3, approaching the resolution of
DSA imaging.
Intravascular contrast agents include media such as
gadofosveset trisodium (Vasovist; Bayer Healthcare Phar-
maceuticals, Montville, NJ) (protein binding) for visceral
and peripheral vessels, and gadomer (macromolecule) for
cardiac and coronary MR evaluations. Gadomer-17 (Bayer)
is a synthetic agent with a large molecular weight that is
linked to gadolinium. The renal excretion is slow because of
its size, and, thus, it provides longer vascular enhancement.
An arterial plaque-specific research contrast agent is being
investigated (Gadofluorine; Bayer) in hopes of detecting
stability of arterial plaques.
Vasovist reversibly binds to serum albumin, which results
in longer and significantly greater (16 times) vascular
enhancement. In addition to providing excellent first-pass
MRA analysis, it also provides prolonged serum retention
and delayed extravasation. Advantages of Vasovist include
reduced contrast volumes (<10 mL, 0.03 mmol/kg), superior
spatial resolution (voxel size <0.5 mm3, close to DSA), and
use with longer acquisition times (up to 1 hour), with
repeated imaging if necessary. Current blood pool MRA uses
include body MRV (inferior vena cava/pelvic) and runoff
MRA and MRV cases. Future gadofosveset trisodium
applications may include thoracic MR venography and
vessel wall and plaque analysis. This contrast agent is
excreted primarily by the kidneys and has yet to be impli-
cated in NSF. Its prolonged retention and linear anatomical
configuration may be balanced by its albumin chelation and
low dose demands for MRA examinations.
Conclusion
MRA has come a long way since its initial inception.
There are many new and innovative applications that have
revolutionized the way we look at certain vascular entities.
The authors have chosen just a sampling of the many prac-
tical uses of MRA in body imaging. With so many new
developments, including new techniques and experimental
contrast agents, its clinical applications are sure to become
even more widespread.
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